Free Trial
NASDAQ:ELTX

Elicio Therapeutics Q2 2025 Earnings Report

Elicio Therapeutics EPS Results

Actual EPS
-$0.66
Consensus EPS
-$0.69
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

Elicio Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Elicio Therapeutics Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
Thursday, August 7, 2025
Conference Call Time
4:00PM ET

Elicio Therapeutics Earnings Headlines

Elicio Therapeutics Reports Inducement Grants
This is the “End of Tesla” as we know it…
Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla call alone could have made readers 21 TIMES THEIR MONEY, if they listened to his recommendation. Don't miss his next big prediction.tc pixel
See More Elicio Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Elicio Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Elicio Therapeutics and other key companies, straight to your email.

About Elicio Therapeutics

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.

View Elicio Therapeutics Profile

More Earnings Resources from MarketBeat